BELLUS Health ends NC-503 diabetes development program following results

06-May-2010 - Canada

BELLUS Health announced that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.

"While we are disappointed that the NC-503 indication for Type 2 Diabetes did not prove to be effective, our decision today enables us to preserve shareholder value and conserve our financial and human resources for projects that we believe have high potential for success," said Roberto Bellini, President and Chief Executive Officer of BELLUS Health.

NC-503 (eprodisate disodium, KIACTA(TM)) is a small molecule that is currently being developed for the treatment of AA amyloidosis, a rare disease related to the systemic extracellular deposition of insoluble fibrillar proteins (amyloid) mostly on the kidneys. While eprodisate has been shown to have protective effects on renal function in AA amyloidosis patients in a clinical Phase III study, pre-clinical rodent model data had also suggested that eprodisate had glucose lowering activity and could improve features of metabolic

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance